Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia

 

 Buy Article Permissions and Reprints

ABSTRACT

Serious bleeding and thrombotic complications are frequent in acute promyelocytic leukemia (APL) and are major causes of morbidity and mortality. Microparticles (MP) have been used to study the risk and pathogenesis of thrombosis in many malignant disorders. To date, from published articles, this approach had not been applied to APL. In this article, the hemostatic dysfunction in this disorder is briefly reviewed. A study design to address this problem using MP is described. MP bearing tissue factor, profibrinolytic factors (tissue plasminogen activator and annexin A2), and the antifibrinolytic factor plasminogen activator inhibitor type 1 were measured using flow cytometry. The cellular origin of the MP was identified by specific cell surface markers. Comparison of the various populations of MP was made between samples collected at the time of diagnosis with those collected at molecular remission. Preliminary data suggest that this approach is feasible.

REFERENCES

• 1 Wang Z Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable.  Blood. 2008;  111(5) 2505-2515
  CrossrefPubMedGoogle Scholar
• 2 Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future.  Curr Opin Hematol. 2009;  16(2) 84-91
  CrossrefPubMedGoogle Scholar
• 3 Falanga A, Rickles F R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.  Best Pract Res Clin Haematol. 2003;  16(3) 463-482
  CrossrefPubMedGoogle Scholar
• 4 Kwaan H C, Wang J, Boggio L N. Abnormalities in hemostasis in acute promyelocytic leukemia.  Hematol Oncol. 2002;  20(1) 33-41
  CrossrefPubMedGoogle Scholar
• 5 Tallman M S, Kwaan H C. Intravascular clotting activation and bleeding in patients with hematologic malignancies.  Rev Clin Exp Hematol. 2004;  8(1) E1
  PubMedGoogle Scholar
• 6 Tallman M S, Hakimian D, Kwaan H C, Rickles F R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.  Leuk Lymphoma. 1993;  11(1–2) 27-36
  CrossrefPubMedGoogle Scholar
• 7 Vardiman J W, Thiele J, Arber D A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.  Blood. 2009;  114(5) 937-951
  CrossrefPubMedGoogle Scholar
• 8 de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.  Nature. 1990;  347(6293) 558-561
  CrossrefPubMedGoogle Scholar
• 9 Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment [review].  Hematology(Am Soc Hematol Educ Program. 2006;  156-161, 514
  PubMedGoogle Scholar
• 10 Licht J D. Acute promyelocytic leukemia—weapons of mass differentiation.  N Engl J Med. 2009;  360(9) 928-930
  CrossrefPubMedGoogle Scholar
• 11 Grimwade D, Mistry A R, Solomon E, Guidez F. Acute promyelocytic leukemia: a paradigm for differentiation therapy.  Cancer Treat Res. 2009;  145 219-235
  PubMedGoogle Scholar
• 12 Nasr R, Guillemin M C, Ferhi O et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.  Nat Med. 2008;  14(12) 1333-1342
  CrossrefPubMedGoogle Scholar
• 13 Rego E M, He L Z, Warrell Jr R P, Wang Z G, Pandolfi P P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.  Proc Natl Acad Sci U S A. 2000;  97(18) 10173-10178
  CrossrefPubMedGoogle Scholar
• 14 Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.  J Clin Oncol. 2009;  27(4) 504-510
  CrossrefPubMedGoogle Scholar
• 15 Sirulnik A, Melnick A, Zelent A, Licht J D. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.  Best Pract Res Clin Haematol. 2003;  16(3) 387-408
  CrossrefPubMedGoogle Scholar
• 16 Melnick A, Licht J D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.  Blood. 1999;  93(10) 3167-3215
  CrossrefPubMedGoogle Scholar
• 17 Rego E M, Ruggero D, Tribioli C et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.  Oncogene. 2006;  25(13) 1974-1979
  CrossrefPubMedGoogle Scholar
• 18 Mueller B U, Buerger A U, Solenthaler M et al. Pleural tumors as sole primary manifestation of acute promyelocytic leukemia.  Ann Oncol. 2006;  17(4) 722-723
  CrossrefPubMedGoogle Scholar
• 19 Guibal F C, Alberich-Jorda M, Hirai H et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.  Blood. 2009;  114(27) 5415-5425
  CrossrefPubMedGoogle Scholar
• 20 Park D J, Vuong P T, de Vos S, Douer D, Koeffler H P. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays.  Blood. 2003;  102(10) 3727-3736
  CrossrefPubMedGoogle Scholar
• 21 Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.  Leukemia. 2000;  14(4) 722-726
  CrossrefPubMedGoogle Scholar
• 22 Neame P B, Soamboonsrup P, Leber B et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants.  Am J Hematol. 1997;  56(3) 131-142
  CrossrefPubMedGoogle Scholar
• 23 Rizzatti E G, Portieres F L, Martins S L, Rego E M, Zago M A, Falcão R P. Microgranular and t(11;17)/PLZF-RARalpha variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RARalpha gene rearrangement.  Am J Hematol. 2004;  76(1) 44-51
  CrossrefPubMedGoogle Scholar
• 24 Sanz M A, Grimwade D, Tallman M S et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.  Blood. 2009;  113(9) 1875-1891
  CrossrefPubMedGoogle Scholar
• 25 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.  Blood. 1990;  75(11) 2112-2117
  PubMedGoogle Scholar
• 26 Stein E, McMahon B, Kwaan H, Altman J K, Frankfurt O, Tallman M S. The coagulopathy of acute promyelocytic leukaemia revisited.  Best Pract Res Clin Haematol. 2009;  22(1) 153-163
  CrossrefPubMedGoogle Scholar
• 27 Jácomo R H, Melo R A, Souto F R et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines.  Haematologica. 2007;  92(10) 1431-1432
  CrossrefPubMedGoogle Scholar
• 28 Di Bona E, Avvisati G, Castaman G et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.  Br J Haematol. 2000;  108(4) 689-695
  CrossrefPubMedGoogle Scholar
• 29 de la Serna J, Montesinos P, Vellenga E et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.  Blood. 2008;  111(7) 3395-3402
  CrossrefPubMedGoogle Scholar
• 30 Kwaan H C. Double hazard of thrombophilia and bleeding in leukemia.  Hematology Am Soc Hematol Educ Program. 2007;  151-157
  PubMedGoogle Scholar
• 31 Tallman M S, Abutalib S A, Altman J K. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.  Semin Thromb Hemost. 2007;  33(4) 330-338
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Escudier S M, Kantarjian H M, Estey E H. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.  Leuk Lymphoma. 1996;  20(5-6) 435-439
  CrossrefPubMedGoogle Scholar
• 33 Goldschmidt N, Gural A, Ben Yehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia.  Leuk Lymphoma. 2003;  44(8) 1433-1437
  CrossrefPubMedGoogle Scholar
• 34 Breccia M, Avvisati G, Latagliata R et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.  Leukemia. 2007;  21(1) 79-83
  CrossrefPubMedGoogle Scholar
• 35 Dally N, Hoffman R, Haddad N, Sarig G, Rowe J M, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia—a single center experience in 34 patients.  Thromb Res. 2005;  116(2) 109-114
  CrossrefPubMedGoogle Scholar
• 36 Polliack A. Acute promyelocytic leukemia with disseminated intravascular coagulation.  Am J Clin Pathol. 1971;  56(2) 155-161
  PubMedGoogle Scholar
• 37 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood. 1992;  79(3) 543-553
  PubMedGoogle Scholar
• 38 Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.  Blood. 1992;  79(2) 534-535
  PubMedGoogle Scholar
• 39 Watanabe R, Murata M, Takayama N Keio Hematology-Oncology Cooperative Study Group (KHOCS) et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia.  Thromb Haemost. 1997;  77(4) 641-645
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Dombret H, Scrobohaci M L, Ghorra P et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.  Leukemia. 1993;  7(1) 2-9
  PubMedGoogle Scholar
• 41 Tallman M S, Lefèbvre P, Baine R M et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2(8) 1341-1350
  CrossrefPubMedGoogle Scholar
• 42 Bennett B, Booth N A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.  Br J Haematol. 1989;  71(4) 511-517
  CrossrefPubMedGoogle Scholar
• 43 Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.  Blood. 1991;  77(9) 1949-1957
  PubMedGoogle Scholar
• 44 Avvisati G, ten Cate J W, Sturk A, Lamping R, Petti M G, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia.  Br J Haematol. 1988;  70(1) 43-48
  CrossrefPubMedGoogle Scholar
• 45 Falanga A, Iacoviello L, Evangelista V et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid.  Blood. 1995;  86(3) 1072-1081
  PubMedGoogle Scholar
• 46 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4).  Blood. 1996;  87(2) 613-617
  PubMedGoogle Scholar
• 47 Drake T A, Ruf W, Morrissey J H, Edgington T S. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line.  J Cell Biol. 1989;  109(1) 389-395
  CrossrefPubMedGoogle Scholar
• 48 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine.  Biochemistry. 1986;  25(14) 4007-4020
  CrossrefPubMedGoogle Scholar
• 49 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115(2) 382-391
  CrossrefPubMedGoogle Scholar
• 50 Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340(13) 994-1004
  CrossrefPubMedGoogle Scholar
• 51 Kwaan H C, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2(2) 306-312
  CrossrefPubMedGoogle Scholar
• 52 Kruithof E K. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.  Thromb Haemost. 2008;  100(6) 969-975
  PubMedGoogle Scholar
• 53 Hultman K, Tjärnlund-Wolf A, Fish R J et al. Retinoids and activation of PKC induce tissue-type plasminogen activator expression and storage in human astrocytes.  J Thromb Haemost. 2008;  6(10) 1796-1803
  CrossrefPubMedGoogle Scholar
• 54 Shah M D, Bergeron A L, Dong J F, López J A. Flow cytometric measurement of microparticles: pitfalls and protocol modifications.  Platelets. 2008;  19(5) 365-372
  CrossrefPubMedGoogle Scholar
• 55 Berckmans R J, Neiuwland R, Böing A N, Romijn F P, Hack C E, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation.  Thromb Haemost. 2001;  85(4) 639-646
  PubMedGoogle Scholar
• 56 Sanz M A, Lo Coco F, Martín G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.  Blood. 2000;  96(4) 1247-1253
  PubMedGoogle Scholar
• 57 Willekens F L, Werre J M, Kruijt J K et al. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors.  Blood. 2005;  105(5) 2141-2145
  CrossrefPubMedGoogle Scholar
• 58 Dasgupta S K, Abdel-Monem H, Niravath P et al. Lactadherin and clearance of platelet-derived microvesicles.  Blood. 2009;  113(6) 1332-1339
  CrossrefPubMedGoogle Scholar
• 59 Furie B, Furie B C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation.  Trends Mol Med. 2004;  10(4) 171-178
  CrossrefPubMedGoogle Scholar
• 60 Deregibus M C, Cantaluppi V, Calogero R et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.  Blood. 2007;  110(7) 2440-2448
  CrossrefPubMedGoogle Scholar

Hau C KwaanM.D. Ph.D. 

Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Olson Pavilion

303 East Chicago Avenue, Chicago, IL 60611

Email: h-kwaan@northwestern.edu